Dr. Reddy's Laboratories lost 5.61% to Rs 2,452.05 at 09:36 IST on BSE after the company received Form-483 with eight observations by the USFDA at the Vishakapatnam facility.
The announcement was made after market hours yesterday, 30 October 2018.Meanwhile, the S&P BSE Sensex was down 27.58 points, or 0.08% to 33,863.55
On the BSE, 34,000 shares were traded in the counter so far compared with average daily volumes of 74,000 shares in the past two weeks. The stock had hit a high of Rs 2,468.90 and a low of Rs 2,425 so far during the day. The stock hit a 52-week high of Rs 2,687.45 on 28 September 2018. The stock hit a 52-week low of Rs 1,888 on 21 May 2018.
Dr. Reddy's Laboratories said that the audit of formulations manufacturing facility at Duvvada, Visakhapatnam, by the USFDA, has been completed. The company received Form-483 with eight observations which it is addressing, Dr. Reddy's Laboratories said.
Dr. Reddy's Laboratories is an integrated pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app